SYS6043 Clinical Trials (2026): 3 Studies for Advanced Metastatic Cancer & Advanced Solid Tumors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
3 SYS6043 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Advanced Metastatic Cancer & Advanced Solid Tumors) and 1,650 total planned enrollment. 3 SYS6043 clinical trials are actively recruiting at 5 U.S. sites across 3 states. Most recent activity: NCT07424547 (Apr 2030).
Where to Participate: All SYS6043 Trial Sites in the U.S. (5 sites across 3 states)
Every actively recruiting SYS6043trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| FL | BRCR Global | Plantation33322 | NCT07424547 | Map |
| FL | Florida Clinical Trials Group | Plantation33322 | NCT07424547 | Map |
| TX | NEXT Oncology Austin | Austin78758 | NCT07424547 | Map |
| TX | NEXT Oncology San Antonio | San Antonio78229 | NCT07424547 | Map |
| VA | NEXT Oncology Virginia | Fairfax22031 | NCT07424547 | Map |
SYS6043 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
| P1/P2 | 2 | 2 |
Recruiting SYS6043 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | P1 | Cancer | 386 | Mar 2026 |
| NCT07241936 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | P1/P2 | Advanced Solid Tumors | 444 | Nov 2025 |
| NCT07415863 | Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors | P1/P2 | Advanced/Metastatic Solid Tumors | 820 | Dec 2024 |
SYS6043 clinical trials by indication
Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07424547 | — | P1 | recruiting | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07241936 | — | P1/P2 | recruiting | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors |
Advanced/Metastatic Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07415863 | — | P1/P2 | recruiting | Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors |
All SYS6043 trials (3)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07424547 | Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | P1 | recruiting | 386 | Conjupro Biotherapeutics, Inc. | Mar 2026 | |
| NCT07241936 | A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors | P1/P2 | recruiting | 444 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Nov 2025 | |
| NCT07415863 | Phase 1/II Clinical Study of SYS6043 in the Treatment of Advanced/Metastatic Solid Tumors | P1/P2 | recruiting | 820 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Dec 2024 |
SYS6043 clinical trials: frequently asked questions
- How many SYS6043 clinical trials are there?
- 3 SYS6043 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants.
- Are SYS6043 clinical trials recruiting in 2026?
- Yes — 3 SYS6043 trials are actively recruiting in 2026, with 5 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is SYS6043 being studied for?
- SYS6043 is being studied for Advanced Metastatic Cancer, Advanced Solid Tumors, Advanced/Metastatic Solid Tumors, Breast Cancer, Cancer and 4 more. The trials are grouped by indication on this page.
- What phase is SYS6043 in?
- SYS6043 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors SYS6043 clinical trials?
- The lead sponsor across the most SYS6043 trials is Conjupro Biotherapeutics, Inc., with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SYS6043as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: